
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd is a commercial-stage biopharmaceutical company with a strong pipeline of monoclonal antibody therapies targeting serious viral infectious diseases, including COVID-19, RSV, measles, and more. The company's lead product, PEMGARDA, has already received emergency use authorization from the FDA and has a strong market potential with a peak penetration of 60% in the US and 30% in the EU. The company's next-generation antibody candidates, including VYD2311 for COVID-19, also have promising data with over 56% of completed treatment days on 4/9. With a robust clinical program, differentiated product profile, and potential for significant revenue growth, Invivyd is positioned for success in the competitive biopharmaceutical market.
Bears say
Invivyd is currently heavily reliant on the success of its mAb for COVID-19, PEMGARDA, which has received emergency use authorization for certain immunocompromised individuals. However, the company's other mAb candidates for COVID-19, VYD2311 and VBY329, are not expected to reach clinical development until 2027, leaving a significant gap in potential revenue for the company. Additionally, the company faces risks from clinical development, competition, novel modality, and commercialization, which could hinder its ability to successfully bring its mAbs to market. These factors contribute to the overall negative outlook on Invivyd's stock.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares